Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in treated coeliac disease
ACTRN12626000177358Phase 4Not yet recruiting
- Sponsor
- WEHI
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hydroxychloroquine in celiac disease (2 cohorts), sponsored by WEHI. Primary endpoint: Whole blood IL-2 level. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
celiac disease
Beyond the preview
Go deeper on ACTRN12626000177358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000177358.